Stock Report

Strides receives USFDA approval for Colchicine Tablets



Posted On : 2022-03-11 11:01:12( TIMEZONE : IST )

Strides receives USFDA approval for Colchicine Tablets

Strides Pharma Science Limited (Strides) today announced that its stepdown wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Colchicine Tablets USP, 0.6 mg from the United States Food & Drug Administration (USFDA). The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Colcrys® Tablets, 0.6 mg, of Takeda Pharmaceuticals U.S.A., Inc. (Takeda).

According to IQVIA MAT January 2022 data, the US market for Colchicine Tablets USP, 0.6 mg is approximately ~US$ 85 Mn. The product will be manufactured at the company's facility at Bengaluru and will be marketed by Strides Pharma Inc. in the US market.

The company has 271 cumulative ANDA filings with USFDA of which 245 ANDAs have been approved and 26 are pending approval.

Shares of Strides Pharma Science Limited was last trading in BSE at Rs. 329.50 as compared to the previous close of Rs. 329.60. The total number of shares traded during the day was 48946 in over 1574 trades.

The stock hit an intraday high of Rs. 337.50 and intraday low of 325.20. The net turnover during the day was Rs. 16151843.00.

Source : Equity Bulls

Keywords

StridesPharmaScience INE939A01011 StridesPharmaGlobal USFDA Approval ColchicineTablets